The emerging functions of the p53-miRNA network in stem cell biology

Cell Cycle

Volumn 11, Issue 11, 2012, Pages 2063-2072

  Lin, Chao Po ^a   Choi, Yong Jin ^a   Hicks, Geoffrey G ^b   He, Lin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Embryonic stem cells; Induced pluripotent stem cells; MicroRNA; miR 34; p53; Stem cells

Indexed keywords

MICRORNA; PROTEIN P53;

ADULT STEM CELL; CANCER INVASION; CELL DIFFERENTIATION; CELL RENEWAL; CYTOLOGY; HUMAN; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOMATIC CELL; STEM CELL;

EID: 84861885141     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20207     Document Type: Review

References (155)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; http://dx.doi.org/10.1126/ science.1905840.
2. Levine AJ, Hu W, Feng Z. The p53 pathway: what questions remain to be explored? Cell Death Differ 2006; 13:1027-36; PMID:16557269; http://dx.doi.org/10.1038/sj.cdd.4401910.
3. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21; PMID:1552940; http://dx.doi.org/ 10.1038/356215a0.
4. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4:1-7; PMID:7922305; http://dx.doi.org/10.1016/S0960-9822(00)00002-6.
5. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 1999; 55:48-63; PMID:10065151; http://dx.doi.org/10.1007/s000180050269.
6. de Keizer PL, Laberge RM, Campisi J. p53: Pro-aging or pro-longevity? Aging (Albany NY) 2010; 2:377-9; PMID:20657035.
7. Poyurovsky MV, Prives C. p53 and aging: A fresh look at an old paradigm. Aging (Albany NY) 2010; 2:380-2; PMID:20657036.
8. Vigneron A, Vousden KH. p53, ROS and senescence in the control of aging. Aging (Albany NY) 2010; 2:471-4; PMID:20729567.
9. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31; PMID:19410540; http://dx.doi.org/10.1016/j.cell. 2009.04.037.
10. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161; http://dx.doi.org/10.1038/nrm2147.
11. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10:1054-72; PMID:8654922; http://dx.doi.org/10.1101/gad.10.9.1054.
12. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12; PMID:18431400; http://dx.doi.org/10.1038/nrm2395.
13. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460:529-33; PMID:19626115; http://dx.doi.org/10.1038/nature08199.
14. Qin H, Yu T, Qing T, Liu Y, Zhao Y, Cai J, et al. Regulation of apoptosis and differentiation by p53 in human embryonic stem cells. J Biol Chem 2007; 282:5842-52; PMID:17179143; http://dx.doi.org/10.1074/jbc.M610464200.
15. Song H, Chung SK, Xu Y. Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. Cell Stem Cell 2010; 6:80-9; PMID:20074536; http://dx.doi.org/10.1016/j.stem.2009.11.016.
16. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R, et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 1998; 8:145-55; PMID:9443911; http://dx.doi.org/10.1016/S0960-9822(98)70061-2.
17. Solozobova V, Rolletschek A, Blattner C. Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage. BMC Cell Biol 2009; 10:46; PMID:19534768; http://dx.doi.org/10.1186/1471-2121-10-46.
18. Hong Y, Stambrook PJ. Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc Natl Acad Sci USA 2004; 101:14443-8; PMID:15452351; http://dx.doi.org/10.1073/pnas. 0401346101.
19. Solozobova V, Blattner C. Regulation of p53 in embryonic stem cells. Exp Cell Res 2010; 316:2434-46; PMID:20542030; http://dx.doi.org/10.1016/j.yexcr. 2010.06.006.
20. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005; 7:165-71; PMID:15619621; http://dx.doi.org/10. 1038/ncb1211.
21. Sabapathy K, Klemm M, Jaenisch R, Wagner EF. Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J 1997; 16:6217-29; PMID:9321401; http://dx.doi.org/10.1093/emboj/16.20.6217.
22. Maimets T, Neganova I, Armstrong L, Lako M. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene 2008; 27:5277-87; PMID:18521083; http://dx.doi.org/10.1038/onc.2008.166.
23. Lee KH, Li M, Michalowski AM, Zhang X, Liao H, Chen L, et al. A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells. Proc Natl Acad Sci USA 2010; 107:69-74; PMID:20018659; http://dx.doi.org/10.1073/pnas.0909734107.
24. Aylon Y, Oren M. New plays in the p53 theater. Curr Opin Genet Dev 2011; 21:86-92; PMID:21317061; http://dx.doi.org/10.1016/j.gde.2010.10.002.
25. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-72; PMID:18035408; http://dx.doi.org/10.1016/j.cell. 2007.11.019.
26. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-76; PMID:16904174; http://dx.doi.org/10.1016/j.cell.2006.07.024.
27. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318:1917-20; PMID:18029452; http://dx.doi.org/10.1126/science. 1151526.
28. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26:1269-75; PMID:18849973; http://dx.doi.org/10.1038/nbt.1502.
29. Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009; 5:491-503; PMID:19818703; http://dx.doi.org/10.1016/j.stem.2009.09.012.
30. Li W, Zhou H, Abujarour R, Zhu S, Young Joo J, Lin T, et al. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 2009; 27:2992-3000; PMID:19839055.
31. Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol 2008; 6:253; PMID:18942890; http://dx.doi.org/10.1371/journal.pbio. 0060253.
32. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7:618-30; PMID:20888316; http://dx.doi.org/10.1016/j.stem.2010.08.012.
33. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4:472-6; PMID:19481515; http://dx.doi.org/10. 1016/j.stem.2009.05.005.
34. Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011; 8:376-88; PMID:21474102; http://dx.doi.org/ 10.1016/j.stem.2011.03.001.
35. Lin SL, Chang DC, Lin CH, Ying SY, Leu D, Wu DT. Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Res 2011; 39:1054-65; PMID:20870751; http://dx.doi.org/10.1093/nar/gkq850.
36. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011; 8:633-8; PMID:21620789; http://dx.doi.org/10.1016/j.stem. 2011.05.001.
37. Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, et al. Adult mice generated from induced pluripotent stem cells. Nature 2009; 461:91-4; PMID:19672243; http://dx.doi.org/10.1038/nature08310.
38. Kang L, Wang J, Zhang Y, Kou Z, Gao S. iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell 2009; 5:135-8; PMID:19631602; http://dx.doi.org/10.1016/j.stem.2009.07.001.
39. Zhao Y, Yin X, Qin H, Zhu F, Liu H, Yang W, et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008; 3:475-9; PMID:18983962; http://dx.doi.org/10.1016/j.stem.2008.10.002.
40. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009; 460:1132-5; PMID:19668191; http://dx.doi.org/10.1038/nature08235.
41. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460:1140-4; PMID:19668186; http://dx.doi.org/10.1038/nature08311.
42. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009; 460:1136-9; PMID:19668188; http://dx.doi.org/10.1038/nature08290.
43. Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009; 460:1149-53; PMID:19668189; http://dx.doi.org/10.1038/ nature08287.
44. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009; 460:1145-8; PMID:19668190; http://dx.doi.org/10.1038/ nature08285.
45. Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature 2009; 460:1085-6; PMID:19713919; http://dx.doi.org/10.1038/4601085a.
46. Menendez S, Camus S, Izpisua Belmonte JC. p53: guardian of reprogramming. Cell Cycle 2010; 9:3887-91; PMID:20948296; http://dx.doi.org/10.4161/cc.9.19. 13301.
47. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009; 462:595-601; PMID:19898493; http://dx.doi.org/10.1038/nature08592.
48. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev 2009; 23:2134-9; PMID:19696146; http://dx.doi.org/10.1101/gad.1811609.
49. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol 2011; 13:1353-60; PMID:22020437; http://dx.doi.org/10.1038/ncb2366.
50. Smith ZD, Nachman I, Regev A, Meissner A. Dynamic single-cell imaging of direct reprogramming reveals an early specifying event. Nat Biotechnol 2010; 28:521-6; PMID:20436460; http://dx.doi.org/10.1038/nbt.1632.
51. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045- 5.
52. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005; 309:1519-24; PMID:16141061; http://dx.doi.org/10.1126/science.1111444.
53. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5:522-31; PMID:15211354; http://dx.doi.org/10. 1038/nrg1379.
54. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004; 431:343-9; PMID:15372041; http://dx.doi.org/10.1038/nature02873.
55. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007; 17:118-26; PMID:17197185; http://dx.doi.org/10.1016/j.tcb.2006.12.007.
56. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68:10094-104; PMID:19074875; http://dx.doi.org/10.1158/0008- 5472.CAN-08-1569.
57. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13:317-23; PMID:21336307; http://dx.doi.org/10.1038/ ncb2173.
58. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Trans-activation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745-52; PMID:17540599; http://dx.doi.org/10.1016/j.molcel.2007.05.010.
59. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 2008; 68:10105-12; PMID:19074876; http://dx.doi.org/10.1158/0008-5472.CAN-08-1846.
60. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447:1130-4; PMID:17554337; http://dx.doi.org/10.1038/nature05939.
61. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208:875-83; PMID:21518799; http://dx.doi.org/10.1084/jem. 20110235.
62. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26:731-43; PMID:17540598; http://dx.doi.org/10.1016/j. molcel.2007.05.017.
63. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106:3207-12; PMID:19202062; http://dx.doi.org/10.1073/pnas.0808042106.
64. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010; 107:6334-9; PMID:20308559; http://dx.doi.org/10.1073/pnas. 0911082107.
65. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17:1298-307; PMID:17656095; http://dx.doi.org/10.1016/j.cub.2007.06.068.
66. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6:1586-93; PMID:17554199; http://dx.doi.org/10.4161/cc.6.13.4436.
67. Tarantino C, Paolella G, Cozzuto L, Minopoli G, Pastore L, Parisi S, et al. miRNA 34a, 100 and 137 modulate differentiation of mouse embryonic stem cells. FASEB J 2010; 24:3255-63; PMID:20439489; http://dx.doi.org/10.1096/fj.09- 152207.
68. Agostini M, Tucci P, Killick R, Candi E, Sayan BS, Rivetti di Val Cervo P, et al. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci USA 2011; 108:21093-8; PMID:22160687; http://dx.doi.org/10.1073/pnas.1112061109.
69. Agostini M, Tucci P, Steinert JR, Shalom-Feuerstein R, Rouleau M, Aberdam D, et al. microRNA-34a regulates neurite outgrowth, spinal morphology and function. Proc Natl Acad Sci USA 2011; 108:21099-104; PMID:22160706; http://dx.doi.org/10.1073/pnas.1112063108.
70. Aranha MM, Santos DM, Solá S, Steer CJ, Rodrigues CM. miR-34a regulates mouse neural stem cell differentiation. PLoS One 2011; 6:21396; PMID:21857907; http://dx.doi.org/10.1371/journal.pone.0021396.
71. Bouhallier F, Allioli N, Lavial F, Chalmel F, Perrard MH, Durand P, et al. Role of miR-34c microRNA in the late steps of spermatogenesis. RNA 2010; 16:720-31; PMID:20150330; http://dx.doi.org/10.1261/rna.1963810.
72. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 2011; 4:71; PMID:22045851; http://dx.doi.org/10.1126/scisignal.2001744.
73. Merkel O, Asslaber D, Piñón JD, Egle A, Greil R. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle 2010; 9:2764-8; PMID:20581456; http://dx.doi.org/10.4161/cc.9.14. 12267.
74. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008; 27:5204-13; PMID:18504438; http://dx.doi.org/10.1038/onc.2008.154.
75. Jain AK, Allton K, Iacovino M, Mahen E, Milczarek RJ, Zwaka TP, et al. p53 Regulates Cell Cycle and MicroRNAs to Promote Differentiation of Human Embryonic Stem Cells. PLoS Biol 2012; 10:1001268; PMID:22389628; http://dx.doi.org/10.1371/journal.pbio.1001268.
76. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2 and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137:647-58; PMID:19409607; http://dx.doi.org/10.1016/j.cell. 2009.02.038.
77. Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010; 7:64-77; PMID:20621051; http://dx.doi.org/10.1016/j.stem.2010.04.015.
78. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U, et al. miR-34 and SNAIL form a doublenegative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10:4256-71.
79. Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol 2011; 195:417-33; PMID:22024162; http://dx.doi.org/10.1083/jcb. 201103097.
80. Li Z, Yang CS, Nakashima K, Rana TM. Small RNAmediated regulation of iPS cell generation. EMBO J 2011; 30:823-34; PMID:21285944; http://dx.doi.org/10. 1038/emboj.2011.2.
81. Yang CS, Li Z, Rana TM. microRNAs modulate iPS cell generation. RNA 2011; 17:1451-60; PMID:21693621; http://dx.doi.org/10.1261/rna.2664111.
82. Ory B, Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family crosstalk meets therapeutic opportunity. Oncotarget 2011; 2:259-64; PMID:21436470.
83. Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008; 134:521-33; PMID:18692474; http://dx.doi.org/10.1016/j.cell.2008.07.020.
84. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 2006; 20:2687-700; PMID:17015431; http://dx.doi.org/10.1101/gad.1447006.
85. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. Nat Genet 2008; 40:1478-83; PMID:18978791; http://dx.doi.org/10.1038/ng.250.
86. Zheng GX, Ravi A, Calabrese JM, Medeiros LA, Kirak O, Dennis LM, et al. A latent pro-survival function for the mir-290-295 cluster in mouse embryonic stem cells. PLoS Genet 2011; 7:1002054; PMID:21573140; http://dx.doi.org/10. 1371/journal.pgen.1002054.
87. Neveu P, Kye MJ, Qi S, Buchholz DE, Clegg DO, Sahin M, et al. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell 2010; 7:671-81; PMID:21112562; http://dx.doi.org/10.1016/j.stem. 2010.11.012.
88. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85alpha and CDC42. Nat Struct Mol Biol 2009; 16:23-9; PMID:19079265; http://dx.doi.org/10.1038/nsmb.1533.
89. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, et al. NFkappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14:369-81; PMID:18977326; http://dx.doi.org/10.1016/j.ccr.2008.10.006.
90. Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, et al. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 2010; 9:3277-85; PMID:20703086; http://dx.doi.org/10. 4161/cc.9.16.12598.
91. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 2010; 16:1134-40; PMID:20871609; http://dx.doi.org/10.1038/nm.2227.
92. Zhang Y, Gao JS, Tang X, Tucker LD, Quesenberry P, Rigoutsos I, et al. MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett 2009; 583:3725-30; PMID:19818772; http://dx.doi.org/10.1016/j.febslet.2009.10. 002.
93. Bonizzi G, Cicalese A, Insinga A, Pelicci PG. The emerging role of p53 in stem cells. Trends Mol Med 2012; 18:6-12; PMID:21907001; http://dx.doi.org/10. 1016/j.molmed.2011.08.002.
94. Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, et al. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One 2008; 3:3707; PMID:19002260; http://dx.doi.org/10. 1371/journal.pone.0003707.
95. Solozobova V, Blattner C. p53 in stem cells. World J Biol Chem 2011; 2:202-14; PMID:21949570; http://dx.doi.org/10.4331/wjbc.v2.i9.202.
96. Gil-Perotin S, Marin-Husstege M, Li J, Soriano-Navarro M, Zindy F, Roussel MF, et al. Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors. J Neurosci 2006; 26:1107-16; PMID:16436596; http://dx.doi.org/10.1523/JNEUROSCI.3970 05.2006.
97. Meletis K, Wirta V, Hede SM, Nistér M, Lundeberg J, Frisén J. p53 suppresses the self-renewal of adult neural stem cells. Development 2006; 133:363-9; PMID:16368933; http://dx.doi.org/10.1242/dev.02208.
98. Tedeschi A, Nguyen T, Puttagunta R, Gaub P, Di Giovanni S. A p53-CBP/p300 transcription module is required for GAP-43 expression, axon outgrowth and regeneration. Cell Death Differ 2009; 16:543-54; PMID:19057620; http://dx.doi.org/10.1038/cdd.2008.175.
99. Billon N, Terrinoni A, Jolicoeur C, McCarthy A, Richardson WD, Melino G, et al. Roles for p53 and p73 during oligodendrocyte development. Development 2004; 131:1211-20; PMID:14960496; http://dx.doi.org/10.1242/dev.01035.
100. Nagao M, Campbell K, Burns K, Kuan CY, Trumpp A, Nakafuku M. Coordinated control of self-renewal and differentiation of neural stem cells by Myc and the p19ARF-p53 pathway. J Cell Biol 2008; 183:1243-57; PMID:19114593; http://dx.doi.org/10.1083/jcb.200807130.
101. Armesilla-Diaz A, Bragado P, Del Valle I, Cuevas E, Lazaro I, Martin C, et al. p53 regulates the self-renewal and differentiation of neural precursors. Neuroscience 2009; 158:1378-89; PMID:19038313; http://dx.doi.org/10.1016/j. neuroscience.2008.10.052.
102. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 1995; 5:931-6; PMID:7583151; http://dx.doi.org/10.1016/S0960-9822(95)00183-7.
103. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 1995; 10:175-80; PMID:7663512; http://dx.doi.org/10.1038/ng0695-175.
104. Ostrakhovitch EA, Semenikhin OA. p53-mediated regulation of neuronal differentiation via regulation of dual oxidase maturation factor 1. Neurosci Lett 2011; 494:80-5; PMID:21362455; http://dx.doi.org/10.1016/j.neulet.2011.02. 061.
105. Attar EC, Scadden DT. Regulation of hematopoietic stem cell growth. Leukemia 2004; 18:1760-8; PMID:15457182; http://dx.doi.org/10.1038/sj.leu. 2403515.
106. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009; 4:37-48; PMID:19128791; http://dx.doi.org/10.1016/j.stem.2008.11.006.
107. Dumble M, Moore L, Chambers SM, Geiger H, Van Zant G, Goodell MA, et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 2007; 109:1736-42; PMID:17032926; http://dx.doi.org/10.1182/blood- 2006-03-010413.
108. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005; 11:1306-13; PMID:16286925; http://dx.doi.org/10.1038/nm1320.
109. Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 2010; 6:309-22; PMID:20362536; http://dx.doi.org/10.1016/j.stem.2010.03.002.
110. Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, et al. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 2010; 9:3277-85; PMID:20703086; http://dx.doi.org/10. 4161/cc.9.16.12598.
111. Armesilla-Diaz A, Elvira G, Silva A. p53 regulates the proliferation, differentiation and spontaneous transformation of mesenchymal stem cells. Exp Cell Res 2009; 315:3598-610; PMID:19686735; http://dx.doi.org/10.1016/j.yexcr. 2009.08.004.
112. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460:705-10; PMID:19578358.
113. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009; 138:1083-95; PMID:19766563; http://dx.doi.org/10. 1016/j.cell.2009.06.048.
114. Holtz M, Forman SJ, Bhatia R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res 2007; 67:1113-20; PMID:17283145; http://dx.doi.org/10. 1158/0008-5472.CAN-06-2014.
115. Shing DC, Trubia M, Marchesi F, Radaelli E, Belloni E, Tapinassi C, et al. Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. J Clin Invest 2007; 117:3696-707; PMID:18037989.
116. Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010; 24:1389-402; PMID:20595231; http://dx.doi.org/10.1101/gad. 1940710.
117. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40:499-507; PMID:18443585; http://dx.doi.org/10.1038/ng.127.
118. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17:211-5; PMID:21240262; http://dx.doi.org/10. 1038/nm.2284.
119. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 2010; 9:1031-6; PMID:20190569; http://dx.doi.org/10.4161/cc.9.6.10987.
120. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458:223-7; PMID:19182780; http://dx.doi.org/10. 1038/nature07672.
121. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106:11667-72; PMID:19571010; http://dx.doi.org/10.1073/pnas.0904715106.
122. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010; 142:409-19; PMID:20673990; http://dx.doi.org/10.1016/j.cell.2010.06.040.
123. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 2011; 477:295-300; PMID:21874018; http://dx.doi.org/10.1038/nature10398.
124. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17:193-9; PMID:19461653; http://dx.doi.org/10.1038/cdd.2009.56.
125. Lal A, Thomas MP, Altschuler G, Navarro F, O'Day E, Li XL, et al. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet 2011; 7:1002363; PMID:22102825; http://dx.doi.org/10.1371/journal.pgen.1002363.
126. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8:266; PMID:18803879; http://dx.doi.org/10.1186/1471-2407-8- 266.
127. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7:2591-600; PMID:18719384; http://dx.doi.org/10. 4161/cc.7.16.6533.
128. Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S, Lee B. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood 2009; 114:404-14; PMID:19398721; http://dx.doi.org/10.1182/blood-2008-09 179150.
129. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009; 69:7569-76; PMID:19773441; http://dx.doi.org/10.1158/0008-5472. CAN-09-0529.
130. Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, Lam KK, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010; 31:1037-44; PMID:20351093; http://dx.doi.org/10.1093/carcin/bgq066.
131. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377:114-9; PMID:18834855; http://dx.doi.org/10. 1016/j.bbrc.2008.09.086.
132. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105:13421-6; PMID:18755897; http://dx.doi.org/10.1073/pnas.0801613105.
133. Chen QR, Yu LR, Tsang P, Wei JS, Song YK, Cheuk A, et al. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J Proteome Res 2011; 10:479-87; PMID:21182263; http://dx.doi.org/10. 1021/pr1006697.
134. Markey M, Berberich SJ. Full-length hdmX transcripts decrease following genotoxic stress. Oncogene 2008; 27:6657-66; PMID:18711402; http://dx.doi.org/ 10.1038/onc.2008.266.
135. Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Röh S, Hoffmann R, et al. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics 2011; 10; PMID:21566225; http://dx.doi.org/10.1074/mcp.M111.010462.
136. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 2011; 30:2888-99; PMID:21317930; http://dx.doi.org/ 10.1038/onc.2011.13.
137. Rao DS, O'Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 2010; 33:48-59; PMID:20598588; http://dx.doi.org/10.1016/j.immuni.2010.06.013.
138. Yang B, Guo H, Zhang Y, Chen L, Ying D, Dong S. MicroRNA-145 regulates chondrogenic differentiation of mesenchymal stem cells by targeting Sox9. PLoS One 2011; 6:21679; PMID:21799743; http://dx.doi.org/10.1371/journal.pone. 0021679.
139. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 2010; 5:8836; PMID:20098684; http://dx.doi.org/10.1371/journal.pone.0008836.
140. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med 2010; 16:49-58; PMID:19898489; http://dx.doi.org/10.1038/nm.2054.
141. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology 2009; 77:12-21; PMID:19439999; http://dx.doi.org/10.1159/000218166.
142. Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 2011; 8:125-31; PMID:21289483; http://dx.doi.org/10.4161/rna.8.1.14259.
143. Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 2011; 38:1093-101; PMID:21258769.
144. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al.
145. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102:883-91; PMID:20160723; http://dx.doi.org/10.1038/sj.bjc.6605570.
146. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009; 23:2166-78; PMID:19720868; http://dx.doi.org/10.1101/gad.1842409.
147. Feng S, Cong S, Zhang X, Bao X, Wang W, Li H, et al. MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res 2011; 39:6669-78; PMID:21511813; http://dx.doi.org/10.1093/nar/gkr232.
148. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194 and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18:367-81; PMID:20951946; http://dx.doi.org/10.1016/j.ccr.2010.09.005.
149. Feng L, Xie Y, Zhang H, Wu Y. miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol 2011; PMID:21264532; http://dx.doi.org/10.1007/s12032-011- 9823-1.
150. Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN, et al. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cε. Oncogene 2011; In press; PMID:22158047; http://dx.doi.org/10.1038/onc.2011.565.
151. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601; PMID:18376396; http://dx.doi.org/10.1038/ncb1722.
152. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283:14910-4; PMID:18411277; http://dx.doi.org/10.1074/jbc.C800074200.
153. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11:1487-95; PMID:19935649; http://dx.doi.org/10. 1038/ncb1998.
154. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17:1101-8; PMID:21822286; http://dx.doi.org/10.1038/nm.2401.
155. Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C. p53-Dependent induction of PVT1 and miR-1204. J Biol Chem 2012; 287:2509-19; PMID:22110125; http://dx.doi.org/10.1074/jbc.M111.322875.